Developing treatments that change lives

Claim My Business
Security Type
Common Stock
Technology, Healthcare & Medical
Min Investment
Offering Date
June 17, 2022
Expected Close Date
December 14, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

AiViva is a clinical stage biotech company which has created proprietary technology and new treatments to address significant, unmet medical needs in ophthalmology, dermatology, urology, and oncology. The company is led by a team of seasoned industry experts who have an outstanding track record in successful drug development, commercialization, and multiple IPOs on the NYSE and NASDAQ.


StartEngine OWNERS Exclusive Click here to learn more

$400+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

Super Early Bird Bonus
Invest within the first two weeks and receive 15% bonus shares





$1,000+ Investment
$1,000+ 5% bonus shares

$2,000+ Investment
$2,000+ 5% bonus shares

$5,000+ Investment
$5,000+ 10% bonus shares, plus ability to vote on product names

$10,000+ Investment
$10,000+ 15% bonus shares, Zoom Meeting with Founding Team

$25,000+ Investment
$25,000+ 20% bonus shares, In-person Meeting with Founding Team

Key Deal Facts

AiViva already has successfully raised over $25 million USD, with $4.2 million raised in 2022 alone.

Our diverse product pipeline presents a combined revenue potential of $5.3B. We have four clinical trials (two ongoing, two planned) focused on wet AMD, prostate disorders, and non-melanoma skin cancer.

We have a veteran team with over 300 years of combined experience. AiViva is rated as a top 20 BioPharma company in 2022 by Life Sciences Review.

Management Team / Advisory Board Bios

Diane Tang-Liu, Ph.D., FAAPS, FCP

Chief Executive Officer & Director

Co-founder, CEO and Board Director, AiViva BioPharma, Inc.
Co-founder, Allgenesis, Inc.
Previously Diane has held various senior executive positions at Allergan, Inc. where she built and led R&D programs for 30 years. She is a full adjunct professor of Pharmacology and Pharmaceutical Sciences and Regulatory and Quality Sciences at the University of Southern California and served as a full adjunct professor of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. She published extensively and holds many patents. Diane received many awards and is Elected fellow, American Association of Pharmaceutical Scientists and American College of Clinical Pharmacology.

Johnson Y.N. Lau, MBBS, MD, FRCP

Board of Director

Chief Executive Officer and Board Chairman of Athenex (ATNX), IPO for $75M in 2017, listed in Nasdaq.
Johnson was Chief Executive Officer, Ribapharm, IPO in 2002 for $299 M. It was listed in NYSE and the second largest biotech IPO in history at that time. Previously he was Head of Worldwide Research and Development, ICN Pharmaceuticals and Senior Director of Antiviral Therapy, Schering-Plough. He contributed more than 250 scientific publications and editorials/reviews/chapters.

Larry Hsu Ph.D.

Board of Director

Larry was Co-Founder, President and CEO of Impax Laboratories (IPXL) and led a reverse acquisition (1999). IPXL was listed in Nasdaq with a market cap of about $3 billion at the time of his retirement from the Impax.
Chairman & CEO, LifeMax Healthcare International.
Chairman & CEO, AmMax Bio.
Chairman & CEO, LifeMax Labs.
Chairman & CEO, LifeMax Biotechnology (Taiwan).
Under his leadership, Impax established partnerships with multiple companies including Teva, AstraZeneca, Pfizer and Shire.
LifeMax Labs currently has a partnership with Novartis.
AmMax Bio currently has a partnership with Amgen.

Jinn Wu Ph.D.

Chairman & Director at AiViva Biopharma Inc.

Jinn was Founder and President of XenoBiotic Laboratories, Inc. (XBL) and XBL-China in Nanjing, China.
He served as Adjunct Professor at the University of Medicine and Dentistry of New Jersey (UMDNJ at Rutgers) and Adjunct Professor at The Hong Kong Polytechnic University.

Darlene Deecher, Ph.D.

Vice President Clinical Development

Dr. Deecher has more than 25 years of clinical development and pharmaceutical commercialization. She has led therapeutic portfolios in 3 major drug development sectors including Fortune 500-Pharmaceutical Companies. At Covance she was the strategic leader for phase II-IV trials/programs. She was Senior Vice President of Research, Development and Advocacy at a leading patient organization, the Juvenile Diabetes Research Foundation (JDRF) and led the women’s health research and development programs at Wyeth Pharmaceuticals (Pfizer) for over 15 years.

Shulin Ding, Ph.D.

Executive Director Pharmaceutical Development

Dr. Ding has more than 35 years of drug development and regulatory experience and has been a trailblazer in ophthalmic formulation development. She was Senior Formulation Scientist, Allergan Inc. and was the patent inventor for Restasis, a product achieving over $1 billion in annual sales. Later at Trimeris, Inc., she was responsible for pharmaceutical development of Fuzeon®, a lyophilized parenteral product approved in 2003 by the FDA for the treatment of HIV-1 infection. She was a CMC lead reviewer with the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) for 13 years.

Yi Zhao, MD, Ph.D.

Executive Director Preclinical Development

Dr. Zhao has more than 20 years of applied research experience in translating drug discovery findings to support human clinical testing. He held various scientific positions at Allergan and Vitae Pharmaceuticals. His effects led to clinical development of P450 RAI Inhibitor, 11β-HSD1 inhibitor, BACE inhibitor, RORγt inverse agonist, selective LXRβ agonist, and menin inhibitor for the treatment of dermatological, Type 2 diabetes, Alzheimer’s, auto immune disorders, and leukemias.

Shane Cerrato

Vice President Business Development

Mr. Cerrato has 20+ years of experience in life sciences encompassing, pharmaceutical, biotechnology and medical device space; with, successful leadership disciplines in corporate and business development, global commercial development, product launches, investor relations, strategic marketing and sales management. He has raised capital from international venture capital firms, closed strategic deals with large and small cap companies and led alliance management in cross-functional objectives. He has held progressive leadership positions at Solva Holdings, Bausch + Lomb, Allergan, Valeant Pharmaceuticals, Serono Biotech, Salu Inc., and Pfizer Pharmaceuticals.  He honorably served in the United States Marine Corps with multiple combat deployments in Desert Shield and Desert Storm, and was an elite triathlete competing in Ironman distances including the World Championship in Hawaii.
Mr. Cerrato works full-time as an independent contractor for the Company.

Michael Dorsey

Director of Finance and Accounting

Michael Dorsey joined AiViva BioPharma in 2017 and currently holds the position of Director of Finance and Accounting. 
He has a BS in Biology and Business Administration from the University of Texas at San Antonio.
Amount Raised : $273,240
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter